Improving Prognosis Estimation in Patients with Heart Failure and the Cardiorenal Syndrome

Abdel‐Qadir, Husam; Chugh, Shaan; Lee, Douglas S.

doi:10.4061/2011/351672

Cited by 7 publications

(4 citation statements)

References 137 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, multivariate analysis has not confirmed this finding, probably due to the relatively small proportion of adverse events in our cohort of acute cardiac patients. Furthermore, although our study confirmed the association between increased plasma BNP levels and mortality after acute cardiac events which is in line with negative prognosis associated with BNP among patients with AHF that has been demonstrated earlier ( 19 ), we failed to show prognostic value of BNP in regression analysis.…”

Section: Discussionsupporting

confidence: 72%

Inflammatory Cytokines as Risk Factors for Mortality After Acute Cardiac Events

Hamzić-Mehmedbašić

2016

Med Arh

View full text Add to dashboard Cite

Introduction:Inflammatory markers have been identified as potential indicators of future adverse outcome after acute cardiac events.Aim:This study aimed to analyze baseline inflammatory cytokines levels in patients with acute heart failure (AHF) and/or acute coronary syndrome (ACS) according to survival. The main objective was to identify risk factors for mortality after an episode of AHF and/or ACS.Methods:In this prospective longitudinal study 75 patients with the diagnosis of AHF and/or ACS were enrolled. Baseline laboratory and clinical data were retrieved. Serum and urine interleukin-6 (IL-6) and interleukin-18 (IL-18) levels, plasma B-type natriuretic peptide (BNP) and serum cystatin C values were determined. The primary outcome was in-hospital mortality while secondary outcome was six-month mortality.Results:Median serum and urine IL-6 levels, serum and urine IL-18 levels, as well as median concentrations of plasma BNP and serum cystatin C, were significantly increased in deceased in comparison to surviving AHF and/or ACS patients. Univariate Cox regression analysis identified serum IL-6, serum IL-18, urine IL-6, urine IL-18 as well as serum cystatin C and Acute Physiology and Chronic Health Evaluation (APACHE) II score as risk factors for mortality after an episode of AHF and/or ACS. Multivariate Cox regression analysis revealed that only serum IL-6 is the independent risk factor for mortality after acute cardiac events (HR 61.7, 95% CI 2.1-1851.0; p=0.018).Conclusion:Present study demonstrated the strong prognostic value of serum IL-6 in predicting mortality of patients with AHF and/or ACS.

show abstract

Section: Discussionsupporting

confidence: 72%

Inflammatory Cytokines as Risk Factors for Mortality After Acute Cardiac Events

Hamzić-Mehmedbašić

2016

Med Arh

View full text Add to dashboard Cite

show abstract

“…To date, only a few animal models of cardiorenal syndrome are available for experimentation. [ 1 ] These models are based on rodents, in which cardiac dysfunction can be induced by different means. [ 7 ] These include volume or pressure overload, myocardial ischemia/infarction, toxic injections, and rapid ventricular pacing.…”

Section: Discussionmentioning

confidence: 99%

“…Recent observations from clinical trials have increased the interest in heart-kidney interactions. [ 1 ] Renal dysfunction is considered an independent risk factor for the development of cardiovascular disease and can lead to worse prognosis in patients with hypertension, postmyocardial infarction, and with different degrees of left ventricular dysfunction. [ 2 ] In addition, cardiovascular disease is the leading cause of death in patients with chronic renal failure.…”

Section: Introductionmentioning

confidence: 99%

Rosuvastatin alleviates renal injury in cardiorenal syndrome model rats through anti-inflammatory and antioxidant pathways

Zhou

Zhao

2022

Emerg Crit Care Med

View full text Add to dashboard Cite

Background: Cardiorenal syndrome is increasingly common and has been reported to be associated with inflammation and oxidative stress, and statins have anti-inflammatory and antioxidant effects. Therefore, we designed this experiment to study the preventive effect of statins on cardiorenal syndrome. The aim of the study is to investigate the effect of early rosuvastatin use on cardiorenal syndrome.Method: Forty-five Wistar rats were randomly divided into 3 groups. A unilateral nephrectomy group (Group 1), a unilateral nephrectomy + coronary ligation group (Group 2), and a unilateral nephrectomy + coronary ligation + rosuvastatin group (Group 3). Right kidney removal was performed on all rats during the first week, while Group 3 was given statin intragastric administration at 10 mg/kg/d. One month later, coronary ligation was performed on rats in Groups 2 and 3. Group 3 continued statin treatment. After feeding for 3 months and 2 days, the rats were killed; urine and blood were collected and sent to the laboratory for the determination of the urinary protein/ creatinine ratio and blood lipid, creatinine, and urea nitrogen levels, respectively. Serum interleukin 1β, interleukin 6, malondialdehyde, glutathione peroxidase, angiotensin II, neutrophil gelatinase-associated lipocalin, cystatin C, and B natriuretic peptide levels were also determined. On the day before euthanasia, all rats were anesthetized and examined by cardiac ultrasound. Hematoxylin-eosin and periodic acid-Schiff staining were performed on heart and kidney sections.Results: The ejection fraction in Group 2 was lower than that in Group 1 ( P < 0.01). The ejection fraction value in Group 3 was lower than that in Group 1 ( P < 0.01). Interleukin-1β levels in Group 2 were higher than those in Group 1 ( P < 0.01). Interleukin-1β levels in Group 3 were lower than those in Group 2 ( P < 0.01). The malondialdehyde value in Group 3 was lower than that in Group 2 ( P < 0.05). Histopathology showed that Group 1 had slight renal damage, renal injury was aggravated in Group 2, and renal injury was still present in Group 3, but with alleviated morphology. Conclusion:The interaction of the heart and kidneys in rats is related to inflammation and oxidation. Rosuvastatin can slow down the development of the heart-kidney interaction through anti-inflammatory and antioxidant effects.

show abstract

“…In addition to GFR, the presence and severity of albuminuria and anemia aid in prognostication and management. 490 …”

Section: Rationalementioning

confidence: 99%

Chapter 4: Other complications of CKD: CVD, medication dosage, patient safety, infections, hospitalizations, and caveats for investigating complications of CKD

2013

Kidney International Supplements

View full text Add to dashboard Cite

Improving Prognosis Estimation in Patients with Heart Failure and the Cardiorenal Syndrome

Cited by 7 publications

References 137 publications

Inflammatory Cytokines as Risk Factors for Mortality After Acute Cardiac Events

Inflammatory Cytokines as Risk Factors for Mortality After Acute Cardiac Events

Rosuvastatin alleviates renal injury in cardiorenal syndrome model rats through anti-inflammatory and antioxidant pathways

Chapter 4: Other complications of CKD: CVD, medication dosage, patient safety, infections, hospitalizations, and caveats for investigating complications of CKD

Contact Info

Product

Resources

About